Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2010, 3(9), 2751-2767; doi:10.3390/ph3092751
Review

Clinical Toxicities of Histone Deacetylase Inhibitors

1
, 2
, 3
, 3
 and 3,*
Received: 23 June 2010; in revised form: 18 August 2010 / Accepted: 19 August 2010 / Published: 26 August 2010
(This article belongs to the Special Issue HDAC Inhibitors)
View Full-Text   |   Download PDF [130 KB, uploaded 26 August 2010]
Abstract: The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this family comprises chemical compounds from unrelated chemical classes that have different HDAC isoform specificities, they surprisingly have very similar toxicity profiles. In contrast, the observed toxicity profile is somewhat different from that of traditional cytotoxic chemotherapeutic agents and from other epigenetic agents. While some of the side effects may be familiar to the oncologist, others are less commonly seen. As some patients remain on therapy for a prolonged period of time, the long-term sequelae need to be characterized. In addition, since preclinical models suggest promising activity when used in combination with other antineoplastic agents, combination trials are being pursued. It will thus be important to distinguish the relative toxicity attributed to these agents and be alert to the exacerbation of toxicities observed in single agent studies. Notably, few of the agents in this class have completed phase 2 testing. Consequently, more clinical experience is needed to determine the relative frequency of the observed side effects, and to identify and develop approaches to mitigate potential clinical sequelae.
Keywords: histone deacetylase inhibitors; HDAC; toxicities; chemotherapy; clinical trial; HDI histone deacetylase inhibitors; HDAC; toxicities; chemotherapy; clinical trial; HDI
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Subramanian, S.; Bates, S.E.; Wright, J.J.; Espinoza-Delgado, I.; Piekarz, R.L. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals 2010, 3, 2751-2767.

AMA Style

Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals. 2010; 3(9):2751-2767.

Chicago/Turabian Style

Subramanian, Srividya; Bates, Susan E.; Wright, John J.; Espinoza-Delgado, Igor; Piekarz, Richard L. 2010. "Clinical Toxicities of Histone Deacetylase Inhibitors." Pharmaceuticals 3, no. 9: 2751-2767.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert